Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.6754 -0.1246 (-15.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides Third Quarter 2022 Update
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022 ↗
Upgrades 
Via Benzinga
Mainz Biomed’s Colorectal And Pancreatic Cancer Screening Diagnostics Are More Than Life Savers, They Are Significant Value Drivers ($MYNZ)
Via AB Newswire
Mainz Biomed Best-In-Class Colorectal Cancer Screening Diagnostics Expand International Presence, Targets Billion Dollar Market Opportunities ($MYNZ)
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers 
Via Benzinga
Mainz Biomed Best-In-Class Cancer Screening Diagnostics Tap Into Billion Dollar Market Opportunities ($MYNZ)
Via AB Newswire
Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Power The Move ($MYNZ)
Via AB Newswire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
News headline image
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed (NASDAQ:MYNZ) could storm Wall Street with its molecular genetic diagnostic solutions for life-threatening conditions
Via AB Newswire
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ)
Via AB Newswire
Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)
Via AB Newswire
Topics Bonds Economy Stocks
News headline image
Why GreenBox POS Is Trading Higher By Around 72%, Here Are 70 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers GreenBox POS (NASDAQ: GBOX) shares jumped 72.4% to $2.19 as the company reported better-than-expected Q2 sales. 
Via Benzinga
News headline image
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday ↗
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Nu Holdings, Ally Financial And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year over year and raised FY22 sales guidance above... 
Via Benzinga
News headline image
Why IZEA Worldwide Shares Are Trading Higher By Over 30%: Here Are 37 Stocks Moving Premarket ↗
Gainers IZEA Worldwide, Inc. (NASDAQ: IZEA) shares rose 30.8% to $1.19 in pre-market trading after the company reported a second-quarter revenue increase of 96% year-over-year to $12.58 million,... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022 ↗
Upgrades 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
30 Stocks Moving in Monday's Pre-Market Session ↗
Gainers G Medical Innovations Holdings Ltd (NASDAQ: GMVD) rose 53.6% to $0.5301 in pre-market trading after dropping more than 28% on Friday. 
Via Benzinga
News headline image
93 Biggest Movers From Yesterday ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
News headline image
70 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
87 Biggest Movers From Yesterday ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to... 
Via Benzinga
News headline image
50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 148% to $3.78. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit. Direct... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock rose 222.4% to $4.9 during Wednesday's pre-market session. The company's market cap stands at $21.9 million. TC... 
Via Benzinga
News headline image
31 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 420% to $7.90 in pre-market trading. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.